ProQR Therapeutics N.V (NASDAQ: PRQR) on Friday, soared 2.74% from the previous trading day, before settling in for the closing price of $2.19. Within the past 52 weeks, PRQR’s price has moved between $1.07 and $4.62.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 25.70%. The company achieved an average annual earnings per share of -24.77%. With a float of $71.50 million, this company’s outstanding shares have now reached $105.34 million.
ProQR Therapeutics N.V (PRQR) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of ProQR Therapeutics N.V is 32.04%, while institutional ownership is 37.87%.
ProQR Therapeutics N.V (PRQR) Performance Highlights and Predictions
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.08 earnings per share (EPS) for the period topping the consensus outlook (set at -0.14) by 0.06. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.11 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -24.77% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -14.72% during the next five years compared to 25.70% growth over the previous five years of trading.
ProQR Therapeutics N.V (NASDAQ: PRQR) Trading Performance Indicators
ProQR Therapeutics N.V (PRQR) is currently performing well based on its current performance indicators. A quick ratio of 3.76 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 13.23.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.44, a number that is poised to hit -0.12 in the next quarter and is forecasted to reach -0.58 in one year’s time.
Technical Analysis of ProQR Therapeutics N.V (PRQR)
The latest stats from [ProQR Therapeutics N.V, PRQR] show that its last 5-days average volume of 0.32 million was inferior to 0.42 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 67.62%.
During the past 100 days, ProQR Therapeutics N.V’s (PRQR) raw stochastic average was set at 80.28%, which indicates a significant decrease from 84.91% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.13 in the past 14 days, which was higher than the 0.13 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.16, while its 200-day Moving Average is $2.19. Now, the first resistance to watch is $2.29. This is followed by the second major resistance level at $2.33. The third major resistance level sits at $2.41. If the price goes on to break the first support level at $2.17, it is likely to go to the next support level at $2.09. Assuming the price breaks the second support level, the third support level stands at $2.05.
ProQR Therapeutics N.V (NASDAQ: PRQR) Key Stats
Market capitalization of the company is 236.73 million based on 105,213K outstanding shares. Right now, sales total 20,460 K and income totals -30,040 K. The company made 4,330 K in profit during its latest quarter, and -13,830 K in sales during its previous quarter.
